DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Referenz

Pavel ME. et al.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Lancet 2011;
378: 2005-2012

Bibliographische Angaben herunterladen

Suchen in:
Aufrufen in: